Immuneering Corporation

IMRX · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders13.8%

Institutions55.6%

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	–	$0	$316952	$2.08M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	–	–	$0	$158122	$1.15M
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	–	–	$0	$158830	$926888
Gross profit as a percentage of revenue.	–	–	–	50.1%	44.6%
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$59.38M	-$64.07M	-$58.41M	-$51.74M	-$33.89M
Operating income as a percentage of revenue.	–	–	–	-16325.8%	-1629.2%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$56.02M	-$61.04M	-$53.47M	-$50.51M	-$33.54M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.27	$-2.04	$-1.88	$-1.91	$-2.46
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.27	$-2.04	$-1.88	$-1.90	$-2.46

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$128.65M	$36.14M	$59.41M	$72.64M	$74.89M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$231.99M	$52.71M	$102.58M	$122.37M	$166.70M
Everything the company owes — debt, unpaid bills, and other obligations.	$13.50M	$11.33M	$12.01M	$12.52M	$10.72M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$218.48M	$41.39M	$90.58M	$109.85M	$155.98M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$45.34M	-$55.00M	-$48.97M	-$44.10M	-$30.85M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$142226	$84875	$342746	$742483	$60786
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$45.49M	-$55.08M	-$49.31M	-$44.84M	-$30.91M

	You	Peer avg
Revenue Growth	–	-51.0%
ROE	-52.1%	-85.8%

Immuneering Corporation

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison